Sanofi: agreement with London for vaccine doses
(CercleFinance.com) - The two healthcare giants Sanofi and GSK have announced an agreement with the UK government to supply 60 million doses of their Covid-19 vaccine, subject to the signing of a definitive contract.
"The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology," they said.
They are committed to making this Covid-19 vaccine candidate "affordable and available globally". Discssions are underway with the European Commission, with France and Italy on the negotiating team, and other governments to ensure global access.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology," they said.
They are committed to making this Covid-19 vaccine candidate "affordable and available globally". Discssions are underway with the European Commission, with France and Italy on the negotiating team, and other governments to ensure global access.
Copyright (c) 2020 CercleFinance.com. All rights reserved.